Drugs / interferon β-1b
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04356495 | Jul 2020 → Oct 2021 | COVID-19 | University Hospital, Bordeaux | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon β-1b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04356495 ↗ |
| Known as | EXTAVIA | “of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water” NCT04356495 ↗ |
| Known as | IFN-β-1b | “of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water” NCT04356495 ↗ |